Bahl & Gaynor Inc. cut its stake in Atrion Co. (NASDAQ:ATRI) by 19.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,529 shares of the medical instruments supplier’s stock after selling 602 shares during the period. Bahl & Gaynor Inc. owned approximately 0.14% of Atrion worth $1,644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of ATRI. First Trust Advisors LP grew its position in Atrion by 159.6% in the first quarter. First Trust Advisors LP now owns 3,979 shares of the medical instruments supplier’s stock worth $3,496,000 after acquiring an additional 2,446 shares during the period. Victory Capital Management Inc. raised its stake in shares of Atrion by 93.7% in the fourth quarter. Victory Capital Management Inc. now owns 1,600 shares of the medical instruments supplier’s stock valued at $1,151,000 after acquiring an additional 774 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Atrion by 127.6% in the fourth quarter. Principal Financial Group Inc. now owns 1,994 shares of the medical instruments supplier’s stock valued at $1,498,000 after acquiring an additional 1,118 shares in the last quarter. State Street Corp raised its stake in shares of Atrion by 2.3% in the fourth quarter. State Street Corp now owns 46,560 shares of the medical instruments supplier’s stock valued at $34,990,000 after acquiring an additional 1,066 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Atrion by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,820 shares of the medical instruments supplier’s stock valued at $6,629,000 after buying an additional 127 shares during the last quarter. Institutional investors and hedge funds own 65.79% of the company’s stock.

Separately, BidaskClub lowered Atrion from a “hold” rating to a “sell” rating in a report on Friday, June 19th.

NASDAQ:ATRI traded down $12.77 during trading hours on Friday, hitting $649.13. The company’s stock had a trading volume of 932 shares, compared to its average volume of 5,407. The stock has a market capitalization of $1.20 billion, a P/E ratio of 34.03 and a beta of 0.16. The stock has a fifty day moving average of $654.20 and a 200-day moving average of $677.89. Atrion Co. has a 52-week low of $579.00 and a 52-week high of $867.50.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $4.79 earnings per share (EPS) for the quarter. The company had revenue of $43.59 million for the quarter. Atrion had a return on equity of 15.57% and a net margin of 23.06%.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Monday, June 15th will be issued a dividend of $1.55 per share. This represents a $6.20 annualized dividend and a dividend yield of 0.96%. The ex-dividend date of this dividend is Friday, June 12th.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Further Reading: How can investors invest in the S&P/TSX Index?

Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI).

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.